Synergistic effect of the combination of nanoparticulate Fe3O4 and Au with daunomycin on K562/A02 cells
暂无分享,去创建一个
Feng Gao | Qian Sun | Jun Wang | Jian Cheng | F. Gao | Xue-mei Wang | Yongyuan Dai | Chong Gao | Bao-An Chen | Wenlin Xu | Jian Cheng | Jun Wang | Gang Zhao | Yong-Yuan Dai | Xue-Mei Wang | Ren-Yun Zhang | Wen-Lin Xu | Hui-Ling Shen | Xiao-Jing Deng | Jia-hua Ding | Yun-Yu Sun | Ning-Na Chen | Jiahua Ding | Ning-na Chen | Gang Zhao | Qian Sun | Yun-yu Sun | Bao‐an Chen | Chong Gao | Ren-Yun Zhang | Hui-ling Shen | Xiao-Jing Deng
[1] Y. Hashimoto,et al. Modulation of doxorubicin resistance in a doxorubicin-resistant human leukaemia cell by an immunoliposome targeting transferring receptor. , 1997, British Journal of Cancer.
[2] F. Gao,et al. Novel nanocomposite of nano fe(3)o(4) and polylactide nanofibers for application in drug uptake and induction of cell death of leukemia cancer cells. , 2008, Langmuir : the ACS journal of surfaces and colloids.
[3] T. Litman,et al. Structure-activity relationships of P-glycoprotein interacting drugs: kinetic characterization of their effects on ATPase activity. , 1997, Biochimica et biophysica acta.
[4] Dan Du,et al. Electrochemical immunoassay of membrane P-glycoprotein by immobilization of cells on gold nanoparticles modified on a methoxysilyl-terminated butyrylchitosan matrix. , 2005, Biochemistry.
[5] Chenjie Xu,et al. Linking Hydrophilic Macromolecules to Monodisperse Magnetite (Fe(3)O(4)) Nanoparticles via Trichloro-s-triazine. , 2006, Chemistry of materials : a publication of the American Chemical Society.
[6] P Couvreur,et al. Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin A in polyalkylcyanoacrylate nanoparticles. , 2000, Biomaterials.
[7] P. Twentyman. Cyclosporins as drug resistance modifiers. , 1992, Biochemical pharmacology.
[8] Tim Liedl,et al. Cytotoxicity of colloidal CdSe and CdSe/ZnS nanoparticles. , 2005, Nano letters.
[9] J. Benoit,et al. Etoposide nanocarriers suppress glioma cell growth by intracellular drug delivery and simultaneous P-glycoprotein inhibition. , 2006, Journal of controlled release : official journal of the Controlled Release Society.
[10] F. Baas,et al. Mechanisms of multidrug-resistance , 1994 .
[11] T. Tsuruo,et al. Characterization of the ATPase activity of the Mr 170,000 to 180,000 membrane glycoprotein (P-glycoprotein) associated with multidrug resistance in K562/ADM cells. , 1988, Cancer research.
[12] John A. Kellen,et al. Mechanisms of Multidrug Resistance , 1995 .
[13] D. Leslie-Pelecky,et al. Iron oxide nanoparticles for sustained delivery of anticancer agents. , 2005, Molecular pharmaceutics.
[14] R. Advani,et al. Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar). , 1999, Blood.
[15] P. Couvreur,et al. Doxorubicin-loaded nanospheres bypass tumor cell multidrug resistance. , 1992, Biochemical pharmacology.
[16] F. Gao,et al. Combination of tetrandrine as a potential-reversing agent with daunorubicin, etoposide and cytarabine for the treatment of refractory and relapsed acute myelogenous leukemia. , 2006, Leukemia research.
[17] J C Sanford,et al. Optimizing the biolistic process for different biological applications. , 1993, Methods in enzymology.
[18] X. Shen,et al. Preparation of magnetic polybutylcyanoacrylate nanospheres encapsulated with aclacinomycin A and its effect on gastric tumor. , 2004, World journal of gastroenterology.
[19] B. Chu,et al. Preparation and Properties of Magnetite and Polymer Magnetite Nanoparticles , 1999 .
[20] F. Gao,et al. Synergistic enhancement effect of magnetic nanoparticles on anticancer drug accumulation in cancer cells , 2006, Nanotechnology.
[21] Dong-Hwang Chen,et al. Preparation and characterization of YADH-bound magnetic nanoparticles , 2002 .
[22] L. Ratner,et al. Multidrug resistance transporters and modulation , 2000, Current opinion in oncology.
[23] P Couvreur,et al. Drug delivery to resistant tumors: the potential of poly(alkyl cyanoacrylate) nanoparticles. , 2003, Journal of controlled release : official journal of the Controlled Release Society.
[24] Jianxiang Wang,et al. Expression of sorcin predicts poor outcome in acute myeloid leukemia. , 2003, Leukemia research.
[25] Robert Langer,et al. Microfluidic system for studying the interaction of nanoparticles and microparticles with cells. , 2005, Analytical chemistry.
[26] P. Couvreur,et al. Nanoparticles in cancer therapy and diagnosis. , 2002, Advanced drug delivery reviews.
[27] S. Hegewisch‐Becker. MDR1 reversal: criteria for clinical trials designed to overcome the multidrug resistance phenotype. , 1996, Leukemia.
[28] P. Couvreur,et al. Enhanced cytotoxicity of doxorubicin encapsulated in polyisohexylcyanoacrylate nanospheres against multidrug-resistant tumour cells in culture. , 1994, European journal of cancer.